Source disclosure: February 09, 2026
Kringle Pharma,Inc. [4884.T]
TOKYO, Feb 09 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported a significant impairment loss related to its subsidiary, Kringle Pharma USA, Inc., due to a substantial decline in equity value.
The impairment charge amounts to ¥1.4 million. This non-recurring item will be recorded as a special loss in the first quarter earnings report for the fiscal year ending September 2026.
Despite this development, the company maintains its outlook for the full fiscal year 2026, stating there will be no changes to previously announced forecasts.
AI-translated content. 🟢 Confidence: High See terms • Original filing
💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.